Polianta Ltd Invests $1.66 Million in Globus Medical, Inc. $GMED

Polianta Ltd acquired a new stake in Globus Medical, Inc. (NYSE:GMED) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 21,000 shares of the medical device company’s stock, valued at approximately $1,659,000.

Other large investors also recently bought and sold shares of the company. Invesco Ltd. boosted its holdings in shares of Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after acquiring an additional 3,595,339 shares in the last quarter. Bank of Montreal Can raised its holdings in Globus Medical by 15,317.1% during the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after purchasing an additional 3,351,380 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Globus Medical by 1,303.9% during the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after purchasing an additional 1,908,795 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Globus Medical in the fourth quarter valued at about $90,411,000. Finally, Norges Bank acquired a new stake in Globus Medical in the fourth quarter valued at about $89,922,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the transaction, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. This trade represents a 4.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 18.38% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GMED. Wells Fargo & Company lowered their price objective on Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a report on Friday. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Stifel Nicolaus decreased their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Monday, July 13th. Finally, BMO Capital Markets initiated coverage on Globus Medical in a report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $101.77.

Key Headlines Impacting Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Q2 results exceeded expectations: Globus Medical reported adjusted earnings of $1.34 per share, ahead of the approximately $1.10–$1.12 consensus, while revenue reached $789.6 million versus estimates of $782.9 million. Revenue increased 5.9% year over year, and EPS rose substantially from $0.86 in the prior-year quarter. Globus Medical Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Profit outlook improved: Management raised its fiscal 2026 EPS guidance to $4.95–$5.05, above the prior analyst consensus of $4.74. The earnings call highlighted margin gains, spine-market growth and continued benefits from operating leverage. GMED Q2 Earnings Call Highlights
• Positive Sentiment: Analyst support remains favorable: TD Cowen maintained a Buy rating and a $115 price target, citing reaccelerating spine growth, strong earnings power and robust research-and-development investment. Globus Medical Earns Buy Rating
• Neutral Sentiment: Sales outlook was unchanged: Globus Medical kept fiscal 2026 revenue guidance near $3.2 billion, roughly in line with consensus. This limits the upside from the earnings report but indicates management is maintaining its growth expectations.
• Negative Sentiment: Some execution risks remain: Management cited risks involving Nevro and Enabling Technologies, contributing to caution around revenue growth. Wells Fargo also lowered its price target from $103 to $99, although it retained an Overweight rating. Wells Fargo Analyst Action

Globus Medical Trading Up 1.4%

GMED stock opened at $82.20 on Friday. The company’s 50-day moving average price is $79.33 and its 200 day moving average price is $85.23. Globus Medical, Inc. has a 52 week low of $54.15 and a 52 week high of $101.40. The company has a market cap of $11.16 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.70 and a beta of 0.95.

Globus Medical (NYSE:GMED) last issued its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.24. Globus Medical had a net margin of 17.02% and a return on equity of 14.73%. The company had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. During the same period last year, the company posted $0.86 earnings per share. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities research analysts expect that Globus Medical, Inc. will post 5 earnings per share for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.